Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04128657
Other study ID # LARS_Wexner_MA
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 1, 2019
Est. completion date October 31, 2019

Study information

Verified date February 2020
Source Moroccan Society of Surgery
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In the past decade, colorectal cancer management improved considerably with total mesorectal excision as well as the multidisciplinary management relying on neoadjuvant radiochemotherapy. This forward leap is currently responsible for an increase in the survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the surgical approach is now more inclined towards sphincter preserving procedures, which allows the conservation of body image but can have negative bowel function repercussions consisting of urgency and incontinence ; all these terms encompassed in the low anterior resection syndrome.

In the light of these findings many studies developed assessment tools in order to objectively measure this functional alteration among which are the low anterior resection syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel function after sphincter-preserving surgery are now translated and validated into various languages and used in different countries.

The LARS score relies on the frequency of the symptoms and allows the categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score relies on the examination of the frequency of three types of fecal incontinence (solid, liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency options ranging from never (score 0) through to always (meaning at least once per day; score 4). The score ranges from 0 (perfect continence) to 20 (complete incontinence).

The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan arabic dialect.


Description:

The translation of the LARS and WEXNER score to the moroccan dialect ( arabic ) has been done in another study using translation and back translation in concordance with the international guidelines. The questionnaire is administered to a total of 102 patients either directly or via telephone. Reproducibility will be tested through test and retest as one sub-group will be administered the questionnaire twice with an interval of 1 to 2 weeks. Patients will also be administered the questionnaires of the European Organization for Research and treatment of Cancer (EORTC) : QLQ-C30.

The validity of the LARS and WEXNER score will be tested by using the indicators of discriminant validity and convergent validity which will be determined in this study by computing the correlations between the LARS and WEXNER scores to the EORTC QLQ-C30.

For discriminant validity testing, variables used will be factors known to affect bowel function after colorectal surgery such as gender, age, neoadjuvant therapy, distance of the tumor from the anal verge, prior temporary stoma, length of postoperative period, the need for a reintervention and the occurrence of complications.

We recruited for our study patients treated in the National Oncology Institute of Rabat and in the Al azhar oncology center in the surgical department of Pr. Souadka Abdelilah with a minimum post operative interval of 6 months.

The validation of a moroccan dialectical version of the LARS score and WEXNER score will allow a better understanding of the bowel function post surgery and thereby the identification of patients with the highest scores which will allow a better understanding and possible inclusion of these tools in patient outcome assessment.


Recruitment information / eligibility

Status Completed
Enrollment 143
Est. completion date October 31, 2019
Est. primary completion date October 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients aged older than 18 years.

- Neoplasm of the rectum.

- Rectal cancer patients undergoing curative sphincter-preserving surgery with (partial or total) mesorectal excision.

- Surgery performed between January 2012 to March 2019, with reversal of the defunctioning stoma before March 2019;

- Bowel continuity restoration for at least 6 months.

- Consent to participate in the study.

Exclusion Criteria:

- Palliative surgery.

- The presence of a definitive iliac or perineal stoma.

- Diseases of bowel dysfunction (Crohn's disease)

- Cognitive and/or language issues.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MA_LARS
Validation of the MA_LARS and MA_Wexner

Locations

Country Name City State
Morocco National Institut of Oncology, Surgical oncology department Rabat Please Enter The State Or Province
Morocco Private surgical oncology center Salé

Sponsors (2)

Lead Sponsor Collaborator
Moroccan Society of Surgery Institut National d'Oncologie Sidi Mohammed Ben Abdellah

Country where clinical trial is conducted

Morocco, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of the moroccan arabic version of the LARS score Validation of the Moroccan arabic Low anterior resection syndrome (LARS) score ; 0 to 20 (no LARS), 21 to 29 (minor LARS ) and 30 to 42 (Major LARS ) 6 months after surgery
Primary Validation of the moroccan arabic version of the Wexner score validation of the Moroccan arabic Wexner score; 0 perfect score and 20 complete incontinence 6 months after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT03569488 - Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Among Rectal Cancer Patients
Withdrawn NCT01426074 - DCE-MRI PET Bevacizumab Study in Rectal Cancer Phase 2